This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Welcome back to Endpoints Weekly! This week's recap kicks off with Andrew Dunn's...
Newly-installed FDA Commissioner Marty Makary announced a plan to begin phasing ...
Bristol Myers Squibb’s combined immunotherapies Opdivo and Yervoy won approval t...
An already bleak biotech market has become more daunting for job seekers, partic...
Plus, news about Protagonist Therapeutics, Pfizer and Keros Therapeutics: Ar...
CDMOs fear that FDA site inspections might slow down due to the mass staffing cu...
After 17 years at Genentech, Ira Mellman is joining the Parker Institute for Can...
Two Boston scientists say they have developed a new gene editing tool based on m...
Less than a month after the Trump administration ordered all FDA employees to co...
With US tariffs on pharmaceuticals likely to come "very soon," another of the wo...
In the roughly two months since Robert F. Kennedy Jr. took over as head of HHS, ...
For years, investors have poured billions into mental health startups, making it...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential ne...
Last weekend, researchers gathered in San Diego for the American Academy of Neur...
Alzheon’s controversial, decade-long bet that a failed Alzheimer’s drug could of...